Genzyme news from FierceBiotech
NewsALSO NOTED: Novartis buys bigger stake in Alnylam; FDA chastises ZymoGenetics' marketing campaign;and much more...
> Novartis has scooped up a bigger share of Alnylam stock. The pharma giant now owns 13.3 percent of the company. Read more...
CEO pay: Who makes what in Big Biotech?
What do you get when you make it to the top of of Big Biotech's biggest companies? Millions in compensation, for one thing. But although the average pay for the CEOs listed is $14.42 million, most Read more...
Cholesterol drug delay signals new FDA standards
In what may signal a major shift in FDA standards, Isis and Genzyme say that they expect to add another year to the development timeline for a closely watched cholesterol therapy in order to produce Read more...
Genzyme CEO Henri Termeer - CEO pay report
Henri A. Termeer - Genzyme Total Compensation: $14.6 million Details: Termeer spent part of 2007 convincing investors that, unlike Biogen Idec and MedImmune, Genzyme wasn't a good takeover target. Read more...
Genzyme gets biosimilar rejection, builds R&D plant
The FDA have given a thumbs down to Genzyme's request for permission to sell its Pompe disease drug Read more...
Genzyme gets public backing for $200M expansion
Genzyme is getting some public backing for a $200 million expansion project in the south of Ireland. The Cambridge, MA-based biotech plans to hire about 170 people as it expands its manufacturing and Read more...
Genzyme - Big Biotech's Stock Report
Company: Genzyme Starting stock price: $65.73 Ending stock price: $74.97 Percent Change: 12.97% Scoop: When Biogen Idec put itself up for sale, many wondered whether Genzyme would do the same, Read more...
Big Biotech's Stock Report
2007 was a big year for Big Biotech, and while some of the top companies shined, other industry leaders took a beating. Biotech five biggest players--Amgen (1), Genentech (2), Biogen Idec (3), Read more...
Icahn sells Genzyme stock
Carl Icahn has cashed in his Genzyme chips and evidently gone looking for another game. After arousing intense speculation last year that he would pull an Icahn and shake up Genzyme with big demands Read more...
DEALS: Genzyme, Isis ink $1.9B pact
Genzyme, Isis ink $1.9B pact DEALSWHOWITHWHATSCOOPGenzymeIsis Pharmaceuticals$1.9B dealThe deal is for Isis' promising cardiovascular drug mipomersen, its flagship product. Read more...
| Press ReleasesGenzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen Breakthrough, Potential Blockbuster Product for High Risk Cardiovascular Patients Genzyme and Isis Read more... PRESS RELEASE: FOVEA Pharmaceuticals Enter Into a Research Collaboration in Ophthalmology With GENZYME Corporation FOVEA Pharmaceuticals Enter Into a Research Collaboration in Ophthalmology With GENZYME Corporation PARIS, Nov. 27 -- FOVEA Pharmaceuticals SA. announced today that they have entered into a Read more... PRESS RELEASE: Genzyme Corporation Receives FDA Response Letter on Synvisc-One(TM) Approval in U.S. to be Delayed Genzyme Corporation Receives FDA Response Letter on Synvisc-One(TM) Approval in U.S. to be Delayed CAMBRIDGE, Mass., Nov. 13 /PRNewswire-FirstCall/ -- Genzyme Corp. announced today that it has Read more... PRESS RELEASE: Genzyme Corporation's Epicel Wins Marketing Approval for Severe Burn Victims Genzyme Corporation's Epicel Wins Marketing Approval for Severe Burn Victims CAMBRIDGE, Mass., Oct. 29 -- Genzyme Corporation announced today that the U.S. Food and Drug Administration (FDA) has Read more... PRESS RELEASE: Bioenvision Shareholders Approve Acquisition by Genzyme Corporation Bioenvision Shareholders Approve Acquisition by Genzyme Corporation Genzyme Corporation and Bioenvision announced this afternoon that Bioenvision stockholders have voted to approve the acquisition Read more... |
Get more Genzyme coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight